Windtree Therapeutics, Inc, a US-based biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced the closing of its previously announced public offering of 2,758,620 units at a price to the public of $7.25 per unit and the exercise in full of…